{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T04:58:48Z","timestamp":1692853128715},"reference-count":32,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.therap.2018.06.003","type":"journal-article","created":{"date-parts":[[2018,7,10]],"date-time":"2018-07-10T20:27:25Z","timestamp":1531254445000},"page":"449-460","source":"Crossref","is-referenced-by-count":2,"title":["Xafran, a drug utilization study of rivaroxaban in stroke prevention in atrial fibrillation in France using a claim database"],"prefix":"10.1016","volume":"73","author":[{"given":"Jean","family":"Dallongeville","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Sacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Bou\u00e9e","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinne","family":"Emery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Bureau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Gourmelen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Fauchier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.therap.2018.06.003_bib0165","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1001\/jama.285.18.2370","article-title":"Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study","volume":"285","author":"Go","year":"2001","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.therap.2018.06.003_bib0170","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1001\/jama.1994.03510350050036","article-title":"Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study","volume":"271","author":"Benjamin","year":"1994","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.therap.2018.06.003_bib0175","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1093\/eurheartj\/ehi825","article-title":"Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study","volume":"27","author":"Heeringa","year":"2006","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.therap.2018.06.003_bib0180","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.acvd.2010.11.012","article-title":"Epidemiology of atrial fibrillation in France: extrapolation of international epidemiological data to France and analysis of French hospitalization data","volume":"104","author":"Charlemagne","year":"2011","journal-title":"Arch Cardiovasc Dis"},{"issue":"12","key":"10.1016\/j.therap.2018.06.003_bib0185","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.therap.2018.06.003_bib0190","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0002-9343(98)00389-1","article-title":"Oral anticoagulation in patients with atrial fibrillation: adherence with guidelines in an elderly cohort","volume":"106","author":"White","year":"1999","journal-title":"Am J Med"},{"key":"10.1016\/j.therap.2018.06.003_bib0195","series-title":"EMA. Pradaxa EPAR. EMA Website","author":"EMA","year":"2015"},{"key":"10.1016\/j.therap.2018.06.003_bib0200","series-title":"Xarelto EPAR","author":"E.M.A.","year":"2017"},{"key":"10.1016\/j.therap.2018.06.003_bib0205","series-title":"Eliquis EPAR","author":"E.M.A.","year":"2015"},{"key":"10.1016\/j.therap.2018.06.003_bib0210","doi-asserted-by":"crossref","first-page":"g2116","DOI":"10.1136\/bmj.g2116","article-title":"Anticoagulation in atrial fibrillation","volume":"348","author":"Steinberg","year":"2014","journal-title":"BMJ"},{"issue":"21","key":"10.1016\/j.therap.2018.06.003_bib0215","first-page":"2719","article-title":"Focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010; Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association","volume":"33","author":"Camm","year":"2012","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.therap.2018.06.003_bib0220","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.cjca.2012.01.021","article-title":"Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate\/rhythm control","volume":"28","author":"Skanes","year":"2012","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.therap.2018.06.003_bib0225","author":"H.A.S.","year":"2018","journal-title":"Rapport d\u2019\u00e9valuation des m\u00e9dicaments anticoagulants oraux."},{"key":"10.1016\/j.therap.2018.06.003_bib0230","author":"ANSM","year":"2014"},{"key":"10.1016\/j.therap.2018.06.003_bib0235","series-title":"\u00c9tude en vie r\u00e9elle du b\u00e9n\u00e9fice\/risque \u00e0 court terme des nouveaux anticoagulants oraux (dabigatran, rivaroxaban) chez les patients d\u00e9butant un traitement et non pr\u00e9c\u00e9demment trait\u00e9s par des antivitamines K. ANSM","author":"CNAMTS.","year":"2014"},{"issue":"4","key":"10.1016\/j.therap.2018.06.003_bib0240","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.respe.2010.04.005","article-title":"French national health insurance information system and the permanent beneficiaries sample","volume":"54","author":"Tuppin","year":"2010","journal-title":"Rev Epidemiol Sant\u00e9 Publique"},{"key":"10.1016\/j.therap.2018.06.003_bib0245","series-title":"EMA. Xarelto EPAR","author":"EMA","year":"2009"},{"key":"10.1016\/j.therap.2018.06.003_bib0250","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/1472-6963-12-155","article-title":"Comparison of pharmacy-based measures of medication adherence","volume":"12","author":"Vollmer","year":"2012","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.therap.2018.06.003_bib0255","series-title":"Appropriate use of non-VKA oral anticoagulants","author":"H.A.S.","year":"2014"},{"issue":"13","key":"10.1016\/j.therap.2018.06.003_bib0260","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1161\/CIRCULATIONAHA.115.015710","article-title":"Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study","volume":"132","author":"Maura","year":"2015","journal-title":"Circulation"},{"issue":"14","key":"10.1016\/j.therap.2018.06.003_bib0265","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/eurheartj\/ehv466","volume":"37","author":"Camm","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.therap.2018.06.003_bib0270","doi-asserted-by":"crossref","first-page":"j510","DOI":"10.1136\/bmj.j510","article-title":"Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study","volume":"356","author":"Nielsen","year":"2017","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.therap.2018.06.003_bib0275","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1080\/03007995.2016.1237937","article-title":"Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the United States: the REVISIT-US study","volume":"32","author":"Coleman","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.therap.2018.06.003_bib0280","series-title":"Guideline on good pharmacovigilance practices (GVP)\u00a0\u2013\u00a0Annex I (Rev 3) EMA\/876333\/2011 Rev 3.","author":"E.M.A.","year":"2014"},{"issue":"4","key":"10.1016\/j.therap.2018.06.003_bib0285","first-page":"e150","article-title":"Risk of bleeding and arterial thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-cohort study","volume":"2","author":"Bouillon","year":"2015","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.therap.2018.06.003_bib0290","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1185\/03007995.2014.933577","article-title":"Medication persistence and discontinuation of rivaroxaban versus warfarin among patients with non-valvular atrial fibrillation","volume":"30","author":"Nelson","year":"2014","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"10.1016\/j.therap.2018.06.003_bib0295","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1185\/03007995.2015.1074064","article-title":"Medication persistence and discontinuation of rivaroxaban and dabigatran etexilate among patients with non-valvular atrial fibrillation","volume":"31","author":"Nelson","year":"2015","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.therap.2018.06.003_bib0300","series-title":"\u00c9tude des algorithmes de d\u00e9finition de pathologies dans le systeme national d\u2019information inter-regimes de l\u2019assurance maladie (SNIIRAM)","author":"Quantin","year":"2015"},{"issue":"5","key":"10.1016\/j.therap.2018.06.003_bib0305","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/pds.4192","article-title":"Identifying atrial fibrillation in outpatients initiating oral anticoagulants based on medico-administrative data: results from the French national healthcare databases","volume":"26","author":"Billionnet","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"10.1016\/j.therap.2018.06.003_bib0310","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/bcp.12807","article-title":"A population database study of outcomes associated with vitamin K antagonists in atrial fibrillation before DOAC","volume":"81","author":"Blin","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2018.06.003_bib0315","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ijcard.2016.04.173","article-title":"Predictive ability of HAS-BLED, HEMORR2HAGES, and ATRIA bleeding risk scores in patients with atrial fibrillation. A French nationwide cross-sectional study","volume":"217","author":"Fauchier","year":"2016","journal-title":"Int J Cardiol"},{"issue":"13","key":"10.1016\/j.therap.2018.06.003_bib0320","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1161\/CIRCULATIONAHA.115.015710","article-title":"Comparison of the short-term risk of bleeding and arterial thromboembolic events in non valvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study","volume":"132","author":"Maura","year":"2015","journal-title":"Circulation"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595718301185?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595718301185?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T08:22:11Z","timestamp":1554279731000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595718301185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0040595718301185"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2018.06.003","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]}}}